Akers Biosciences, Inc. Order to Supply PIFA Products to China (3100Z)
December 10 2014 - 2:01AM
UK Regulatory
TIDMAKR
RNS Number : 3100Z
Akers Biosciences, Inc.
10 December 2014
Embargoed: 0700hrs GMT, 10 December 2014
Akers Biosciences, Inc.
$1 Million Initial Order to Supply PIFA Heparin/PF4 Products to
China
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the
"Company"), a leading designer and manufacturer of rapid diagnostic
screening and testing products, announces the receipt of an initial
purchase order (the "Order") valued at US$1,000,000 from NovoTek
Therapeutics Inc. ("NovoTek") to supply PIFA Heparin PF4/Rapid
Assay products in Mainland China ("China").
NovoTek, a Beijing--based pharmaceutical and medical device
business development company, holds the exclusive sales and
marketing rights for the Company's PIFA Heparin/PF4 Rapid Assay
products in China. The Company expects to deliver the Order by
December 31, 2014.
PIFA Heparin/PF4 Rapid Assay and PIFA PLUSS PF4 remain the only
US FDA-cleared rapid manual assays that quickly determine if a
patient being treated with the blood thinner heparin may be
developing a drug allergy. This clinical syndrome known as
heparin--induced thrombocytopenia ("HIT") reverses the heparin's
intended therapeutic effect and transforms it into a clotting
agent. Patients suffering HIT are at risk of developing limb- and
life-threatening complications, so the timely test result provided
by the Company's Heparin/PF4 devices is paramount to effective,
clinical decision making. In the U.S. alone, approximately 12
million patients are exposed to heparin annually and 1% to 5% of
those patients receive a HIT diagnosis. The largest at-risk
populations are patients undergoing major cardiac or orthopedic
surgical procedures.
"We believe China can be a very significant market for the
Company's PIFA Heparin/PF4 Rapid Assay products," said Raymond F.
Akers, Jr. PhD, Co-founder and Executive Chairman of the Board.
"Unlike in the U.S. where we are seeking to disrupt a pre-existing,
slow, expensive, laboratory-based testing method for heparin
platelet factor 4 antibodies, there is, as far as we are aware, no
competing test in China," continued Dr. Akers. "We have been
working with NovoTek for two years to advance the regulatory
approval process required to launch these tests into China. We are
delighted that Akers' tests will be the first approved diagnostic
assay in China to assist in the diagnosis of the allergy to the
widely used blood-thinner, heparin."
"China's healthcare system is improving and the need for
reliable and timely diagnosis is becoming increasingly recognized,"
continued Dr. Akers. "With China's economy growing, we believe it
to be the second biggest potential market in the world for our PIFA
Heparin/PF4 Rapid Assay products. With no competing test of which
are aware, Akers is poised to establish its products as the gold
standard," said Dr. Akers.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid,
point of care screening and testing products designed to bring
healthcare information both rapidly and directly to the consumer or
healthcare provider. The Company has advanced the science of
diagnostics while responding to major shifts in healthcare through
the development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical products distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found on our website at www.akersbiosciences.com. Follow us on
Twitter @AkersBio.
ABOUT NOVOTEK THERAPEUTICS INC.
NovoTek Therapeutics Inc. is a vital part of NovoTek Group, and
is in charge of all international business. To date, NovoTek Group
has grown to seven subsidiary companies focused on pharmaceutical
marketing, medical and IVD products marketing, and contract
research services. NovoTek has its own preclinical research
facility, clinical trial and regulatory teams, and more than 600
sales representatives (500 for pharmaceuticals and 100 for medical
devices) across China. NovoTek has more than 800 employees and more
than 10 local branches nationwide. www.novotekchina.com
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
RedChip Companies, Inc. (US Investor Relations)
Jon Cunningham
Tel. +1 407 644 4256 x107
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel: +44 (0)20 7220 0500
Vigo Communications (UK Investor Relations)
Ben Simons / Alexandra Roper
Tel. +44 (0)20 7016 9570
Email. akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTVKLFBZLFBFBF
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Sep 2023 to Sep 2024